Producer
CSL Behring
Largest plasma fractionator globally; ~33% market share; operates the world's single largest fractionation facility (Broadmeadows, Australia, processing 10M+ liters/year); subsidiary of CSL Limited (ASX: CSL); acquired Vifor Pharma 2022
1
Inputs supplied
1
Goods downstream
1
Facilities
0
Stories
What they make
1 input CSL Behring supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something CSL Behring makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Immunoglobulins (IVIG/SCIG)
40%Albumin
20%Clotting Factors + Hemophilia
20%Specialty Plasma Proteins
20%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Did you know2023
The global supply of plasma-derived therapies (immunoglobulins, albumin, coagulation factors) is structurally dependent on paid plasma donations in the United States — the world's only major country that permits compensation for plasma donation at commercial rates ($30-100 per visit). Europe, Canada, and Australia ban paid plasma donation as a public policy matter (to prevent exploitation of donors and reduce infection risk). CSL Behring and the other major plasma fractionators operate hundreds of US donor centers precisely because paid plasma is the only economically viable volume source. This means global IVIG supply for European immunodeficiency patients is funded by low-income Americans donating plasma two or three times per week at collection centers. When US plasma donation rates decline (as in early COVID-19 when collection centers closed), global IVIG availability drops within months since finished product inventory is typically only 3-6 months. A US policy change banning paid plasma donation would eliminate the supply of most plasma-derived therapies globally.
CSL Behring ↗Origin2023
CSL Limited was originally the Commonwealth Serum Laboratories, established by the Australian government in 1916 to produce vaccines and antiserums for Commonwealth armed forces during World War I. It was Australia's first industrial biotechnology company, producing diphtheria antitoxin, tetanus antitoxin, and later influenza vaccines. The government privatized CSL in 1994 and it listed on the ASX. In 2004, CSL acquired Behring AG (formerly Behringwerke, a German plasma fractionation company established by Emil von Behring — who won the first Nobel Prize in Physiology/Medicine in 1901 for discovering antitoxins). The combined CSL Behring inherited Emil von Behring's scientific legacy and Australia's wartime vaccine program. Today CSL Behring processes over 100 million liters of human plasma annually at the world's largest fractionation facility in Broadmeadows, Victoria, Australia — a facility originally built to serve the Commonwealth of Australia's blood product needs and now serving the global immunoglobulin market.
CSL Behring ↗